Immediate Action

In our continuing effort to provide you with the highest quality toxicology laboratory services available, we have compiled important changes regarding a number of tests we perform. Listed below are the types of changes that may be included in this notification, effective Monday, August 31, 2015

Test Changes - Tests that have had changes to the method/ CPT code, units of measurement, scope of analysis, reference comments, or specimen requirements.

Discontinued Tests - Tests being discontinued with alternate testing suggestions.

Please use this information to update your computer systems/records. These changes are important to ensure standardization of our mutual laboratory databases.

If you have any questions about the information contained in this notification, please call our Client Support Department at (866) 522-2206. Thank you for your continued support of NMS Labs and your assistance in implementing these changes.

The CPT Codes provided in this document are based on AMA guidelines and are for informational purposes only. NMS Labs does not assume responsibility for billing errors due to reliance on the CPT Codes listed in this document.
<table>
<thead>
<tr>
<th>Test Code</th>
<th>Test Name</th>
<th>Method / CPT Code</th>
<th>Specimen Req.</th>
<th>Stability</th>
<th>Scope</th>
<th>Units</th>
<th>Reference Comments</th>
<th>Discontinue</th>
</tr>
</thead>
<tbody>
<tr>
<td>0962B</td>
<td>Cannabidiol, Blood</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0962SP</td>
<td>Cannabidiol, Serum/Plasma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>54003B</td>
<td>Cannabinoids Confirmation (Drug Impaired Driving/DRE Toxicology), Blood (Forensic)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>54029B</td>
<td>Cannabinoids Confirmation (Drug Impaired Driving/DRE Toxicology), Blood (Forensic) (CSA)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>54389B</td>
<td>Cannabinoids Confirmation (Drug Impaired Driving/DRE Toxicology), Blood (Forensic) (CSA)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5646B</td>
<td>Cannabinoids Confirmation, Blood</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>50013B</td>
<td>Cannabinoids Confirmation, Blood (Forensic)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5646FL</td>
<td>Cannabinoids Confirmation, Fluid</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>50013FL</td>
<td>Cannabinoids Confirmation, Fluid (Forensic)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5646SP</td>
<td>Cannabinoids Confirmation, Serum/Plasma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>50013SP</td>
<td>Cannabinoids Confirmation, Serum/Plasma (Forensic)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5646TI</td>
<td>Cannabinoids Confirmation, Tissue</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>50013TI</td>
<td>Cannabinoids Confirmation, Tissue (Forensic)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10034B</td>
<td>Cannabinoids Panel (Drug Impaired Driving-DRE Toxicology), Blood (Forensic) (CSA)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10034SP</td>
<td>Cannabinoids Panel (Drug Impaired Driving-DRE Toxicology), Serum/Plasma (Forensic) (CSA)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0960B</td>
<td>Cannabinoids Panel, Blood</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0960FL</td>
<td>Cannabinoids Panel, Fluid</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0960SP</td>
<td>Cannabinoids Panel, Serum/Plasma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0960TI</td>
<td>Cannabinoids Panel, Tissue</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8892OF</td>
<td>Delta-9 THC (Qualitative), Oral Fluid (Saliva)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5850OF</td>
<td>Delta-9 THC Confirmation (Qualitative), Oral Fluid (Saliva) (Forensic)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1826SP</td>
<td>Dronabinol, Serum/Plasma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8897OF</td>
<td>Drugs of Abuse (7 Panel) (Qualitative), Oral Fluid (Saliva)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8888OF</td>
<td>ProofPOSITIVE® Drug Impaired Driving/DRE Toxicology Cannabinoids (Qualitative), Oral Fluid (Saliva) (CSA)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4155B</td>
<td>Sativex®, Blood</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test Code</td>
<td>Test Name</td>
<td>Method / CPT Code</td>
<td>Specimen Req.</td>
<td>Stability</td>
<td>Scope</td>
<td>Units</td>
<td>Reference Comments</td>
<td>Discontinue</td>
</tr>
<tr>
<td>----------</td>
<td>----------------------------</td>
<td>------------------</td>
<td>---------------</td>
<td>-----------</td>
<td>-------</td>
<td>-------</td>
<td>--------------------</td>
<td>-------------</td>
</tr>
<tr>
<td>4155SP</td>
<td>Sativex®, Serum/Plasma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Test Changes

0962B Cannabidiol, Blood

Summary of Changes: Specimen Requirements were changed. Specimen Requirements (Specimen Container) were changed. Specimen Requirements (Rejection Criteria) were changed. Stability was changed. Reference Comment was changed. Methods/CPT Codes were changed [LC-MS/MS (80349)]

Specimen Requirements: 1 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Gray top tube (Sodium Fluoride / Potassium Oxalate)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Stability: Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)
Scope of Analysis: LC-MS/MS (80349): Cannabidiol

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cannabidiol</td>
<td>ng/mL</td>
<td>Mean peak plasma concentrations of Cannabidiol at approximately 4 hours following dosing with Sativex® at a low dose (5.4 mg of Delta-9 THC and 5.0 mg of Cannabidiol) were 1.6 +/- 0.4 ng/mL and at a high dose (16 mg of Delta-9 THC and 15 mg of Cannabidiol) were 6.7 +/- 2.0 ng/mL. The ratio of whole blood concentration to plasma concentration is unknown for this analyte.</td>
</tr>
</tbody>
</table>

0962SP Cannabidiol, Serum/Plasma

Summary of Changes: Specimen Requirements were changed. Stability was changed. Reference Comment was changed. Methods/CPT Codes were changed [LC-MS/MS (80349)]
Test Changes

Specimen Requirements: 1 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Serum: Collect sample in Red top tube
Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial
using approved guidelines.
Rejection Criteria: Polymer gel separation tube (SST or PST).
Stability: Room Temperature: 30 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)
Scope of Analysis: LC-MS/MS (80349): Cannabidiol

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cannabidiol</td>
<td>ng/mL</td>
<td>Mean peak plasma concentrations of Cannabidiol at approximately 4 hours following dosing with Sativex® at a low dose (5.4 mg of Delta-9 THC and 5.0 mg of Cannabidiol) were 1.6 +/- 0.4 ng/mL and at a high dose (16 mg of Delta-9 THC and 15 mg of Cannabidiol) were 6.7 +/- 2.0 ng/mL.</td>
</tr>
</tbody>
</table>

54029B Cannabinoids Confirmation (Drug Impaired Driving/DRE Toxicology), Blood (Forensic) (CSA)

Summary of Changes: Specimen Requirements were changed.
Specimen Requirements (Specimen Container) were changed.
Stability was changed.
Scope of Analysis was changed.
Order of Reporting was changed.
Methods/CPT Codes were changed [LC-MS/MS (80349)]
Test Changes

Summary of Changes:
Specimen Requirements were changed.
Specimen Requirements (Specimen Container) were changed.
Stability was changed.
Scope of Analysis was changed.
Order of Reporting was changed.
Methods/CPT Codes were changed ([LC-MS/MS (80349)])

Specimen Requirements: 1 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Gray top tube (Sodium Fluoride / Potassium Oxalate)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Stability: Room Temperature: 30 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)
Scope of Analysis: LC-MS/MS (80349): 11-Hydroxy Delta-9 THC, Delta-9 Carboxy THC, Delta-9 THC

54003B Cannabinoids Confirmation (Drug Impaired Driving/DRE Toxicology), Blood (Forensic)

Summary of Changes:
Specimen Requirements were changed.
Specimen Requirements (Specimen Container) were changed.
Stability was changed.
Scope of Analysis was changed.
Order of Reporting was changed.
Methods/CPT Codes were changed ([LC-MS/MS (80349)])

Specimen Requirements: 1 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Gray top tube (Sodium Fluoride / Potassium Oxalate)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Stability: Room Temperature: 30 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)
Scope of Analysis: LC-MS/MS (80349): 11-Hydroxy Delta-9 THC, Delta-9 Carboxy THC, Delta-9 THC

50013B Cannabinoids Confirmation, Blood (Forensic)
Test Changes

Summary of Changes:
Specimen Requirements were changed.
Specimen Requirements (Specimen Container) were changed.
Stability was changed.
Scope of Analysis was changed.
Order of Reporting was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80349)]

Specimen Requirements: 1 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Gray top tube (Sodium Fluoride / Potassium Oxalate)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Stability:
- Room Temperature: 30 day(s)
- Refrigerated: 30 day(s)
- Frozen (-20 °C): 30 day(s)
Scope of Analysis:
- LC-MS/MS (80349): 11-Hydroxy Delta-9 THC, Delta-9 Carboxy THC, Delta-9 THC

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>11-Hydroxy Delta-9 THC</td>
<td>ng/mL</td>
<td>11-Hydroxy Delta-9 THC is an active intermediate metabolite of tetrahydrocannabinol (THC) the active component of marijuana. Usual peak levels: Less than 10% of THC levels after smoking.</td>
</tr>
<tr>
<td>Delta-9 THC</td>
<td>ng/mL</td>
<td>THC concentrations in blood are usually about one-half of serum/plasma concentrations. Usual peak levels in serum for 1.75% or 3.55% THC marijuana cigarettes: 50 - 270 ng/mL at 6 to 9 minutes after beginning smoking, decreasing to less than 5 ng/mL by 2 hrs.</td>
</tr>
</tbody>
</table>

5646B  Cannabinoids Confirmation, Blood

Summary of Changes:
Specimen Requirements were changed.
Specimen Requirements (Specimen Container) were changed.
Stability was changed.
Scope of Analysis was changed.
Order of Reporting was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80349)]
Test Changes

Specimen Requirements: 1 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Gray top tube (Sodium Fluoride / Potassium Oxalate)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Stability: Room Temperature: 30 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)
Scope of Analysis: LC-MS/MS (80349): 11-Hydroxy Delta-9 THC, Delta-9 Carboxy THC, Delta-9 THC

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>11-Hydroxy Delta-9 THC</td>
<td>ng/mL</td>
<td>11-Hydroxy Delta-9 THC is an active intermediate metabolite of tetrahydrocannabinol (THC) the active component of marijuana. Usual peak levels: Less than 10% of THC levels after smoking.</td>
</tr>
<tr>
<td>Delta-9 Carboxy THC</td>
<td>ng/mL</td>
<td>Usual peak levels in serum for 1.75% or 3.55% THC marijuana cigarettes: 10 - 101 ng/mL about 32 to 240 minutes after beginning smoking, with a slow decline. Usually not detectable after passive inhalation.</td>
</tr>
<tr>
<td>Delta-9 THC</td>
<td>ng/mL</td>
<td>THC concentrations in blood are usually about one-half of serum/plasma concentrations. Usual peak levels in serum for 1.75% or 3.55% THC marijuana cigarettes: 50 - 270 ng/mL at 6 to 9 minutes after beginning smoking, decreasing to less than 5 ng/mL by 2 hrs.</td>
</tr>
</tbody>
</table>

50013FL  Cannabinoids Confirmation, Fluid (Forensic)

Summary of Changes: Specimen Requirements were changed.
Scope of Analysis was changed.
Order of Reporting was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80349)]
Test Changes

**Scope of Analysis:** LC-MS/MS (80349): 11-Hydroxy Delta-9 THC, Delta-9 Carboxy THC, Delta-9 THC

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>11-Hydroxy Delta-9 THC</td>
<td>ng/mL</td>
<td>[Reference comment removed]</td>
</tr>
<tr>
<td>Delta-9 THC</td>
<td>ng/mL</td>
<td>No reference data available.</td>
</tr>
</tbody>
</table>

**5646FL Cannabinoids Confirmation, Fluid**

Summary of Changes:
- Specimen Requirements were changed.
- Scope of Analysis was changed.
- Order of Reporting was changed.
- Methods/CPT Codes were changed [LC-MS/MS (80349)]

Specimen Requirements:
- 1 mL Fluid

Transport Temperature: Refrigerated

Specimen Container: Plastic container (preservative-free)

Light Protection: Not Required

Special Handling: None

Rejection Criteria: None

Scope of Analysis: LC-MS/MS (80349): 11-Hydroxy Delta-9 THC, Delta-9 Carboxy THC, Delta-9 THC

**50013SP Cannabinoids Confirmation, Serum/Plasma (Forensic)**

Summary of Changes:
- Specimen Requirements were changed.
- Stability was changed.
- Scope of Analysis was changed.
- Order of Reporting was changed.
- Reference Comment was changed.
- Methods/CPT Codes were changed [LC-MS/MS (80349)]

Specimen Requirements:
- 1 mL Serum or Plasma

Transport Temperature: Refrigerated

Specimen Container: Plastic container (preservative-free)

Light Protection: Not Required

Special Handling:
- Serum: Collect sample in Red top tube
- Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
  Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.

Rejection Criteria: Polymer gel separation tube (SST or PST).

Stability:
- Room Temperature: 14 day(s)
- Refrigerated: 30 day(s)
- Frozen (-20 °C): 30 day(s)
## Test Changes

**Scope of Analysis:** LC-MS/MS (80349): 11-Hydroxy Delta-9 THC, Delta-9 Carboxy THC, Delta-9 THC  
**Method (CPT Code):** LC-MS/MS (80349)

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>11-Hydroxy Delta-9 THC</td>
<td>ng/mL</td>
<td>11-Hydroxy Delta-9 THC is an active intermediate metabolite of tetrahydrocannabinol (THC) the active component of marijuana. Usual peak levels: Less than 10% of THC levels after smoking.</td>
</tr>
<tr>
<td>Delta-9 THC</td>
<td>ng/mL</td>
<td>Usual peak levels in serum for 1.75% or 3.55% THC marijuana cigarettes: 50 - 270 ng/mL at 6 to 9 minutes after beginning smoking, decreasing to less than 5 ng/mL by 2 hrs.</td>
</tr>
</tbody>
</table>

### 5646SP Cannabinoids Confirmation, Serum/Plasma

**Summary of Changes:** Specimen Requirements were changed.  
Stability was changed.  
Scope of Analysis was changed.  
Order of Reporting was changed.  
Reference Comment was changed.  
Methods/CPT Codes were changed [LC-MS/MS (80349)]

**Specimen Requirements:** 1 mL Serum or Plasma  
**Transport Temperature:** Refrigerated  
**Specimen Container:** Plastic container (preservative-free)  
**Light Protection:** Not Required  
**Special Handling:** Serum: Collect sample in Red top tube  
Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.  
**Stability:** Room Temperature: 14 day(s)  
Refrigerated: 30 day(s)  
Frozen (-20 °C): 30 day(s)  
**Rejection Criteria:** Polymer gel separation tube (SST or PST).  
**Scope of Analysis:** 11-Hydroxy Delta-9 THC, Delta-9 Carboxy THC, Delta-9 THC  
**Method (CPT Code):** LC-MS/MS (80349)

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>11-Hydroxy Delta-9 THC</td>
<td>ng/mL</td>
<td>11-Hydroxy Delta-9 THC is an active intermediate metabolite of tetrahydrocannabinol (THC) the active component of marijuana. Usual peak levels: Less than 10% of THC levels after smoking.</td>
</tr>
</tbody>
</table>
Test Changes

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Delta-9 Carboxy THC</td>
<td>ng/mL</td>
<td>Usual peak levels in serum for 1.75% or 3.55% THC marijuana cigarettes: 10 - 101 ng/mL about 32 to 240 minutes after beginning smoking, with a slow decline. Usually not detectable after passive inhalation.</td>
</tr>
<tr>
<td>Delta-9 THC</td>
<td>ng/mL</td>
<td>Usual peak levels in serum for 1.75% or 3.55% THC marijuana cigarettes: 50 - 270 ng/mL at 6 to 9 minutes after beginning smoking, decreasing to less than 5 ng/mL by 2 hrs.</td>
</tr>
</tbody>
</table>

50013TI  Cannabinoids Confirmation, Tissue (Forensic)

Summary of Changes: Test Name was changed. Scope of Analysis was changed. Order of Reporting was changed. Methods/CPT Codes were changed [LC-MS/MS (80349)]

Scope of Analysis: Method (CPT Code) LC-MS/MS (80349): 11-Hydroxy Delta-9 THC, Delta-9 Carboxy THC, Delta-9 THC

5646TI  Cannabinoids Confirmation, Tissue

Summary of Changes: Test Name was changed. Scope of Analysis was changed. Order of Reporting was changed. Methods/CPT Codes were changed [LC-MS/MS (80349)]

Scope of Analysis: Method (CPT Code) LC-MS/MS (80349): 11-Hydroxy Delta-9 THC, Delta-9 Carboxy THC, Delta-9 THC

10034B  Cannabinoids Panel (Drug Impaired Driving-DRE Toxicology), Blood (Forensic) (CSA)

Summary of Changes: Specimen Requirements were changed. Specimen Requirements (Specimen Container) were changed. Stability was changed. Scope of Analysis was changed. Order of Reporting was changed. Methods/CPT Codes were changed [LC-MS/MS (80349)]

Specimen Requirements: 1 mL Blood
Transport Temperature: Refrigerated Specimen Container: Gray top tube (Sodium Fluoride / Potassium Oxalate) Light Protection: Not Required Special Handling: None Rejection Criteria: None
Test Changes

Stability: Room Temperature: 30 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)

Scope of Analysis: LC-MS/MS (80349): 11-Hydroxy Delta-9 THC, Delta-9 Carboxy THC, Delta-9 THC

10034SP Cannabinoids Panel (Drug Impaired Driving-DRE Toxicology), Serum/Plasma (Forensic) (CSA)

Summary of Changes: Specimen Requirements were changed.
Stability was changed.
Scope of Analysis was changed.
Order of Reporting was changed.
Methods/CPT Codes were changed [LC-MS/MS (80349)]

Specimen Requirements: 1 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Serum: Collect sample in Red top tube
Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria: Polymer gel separation tube (SST or PST).
Stability: Room Temperature: 14 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)
Scope of Analysis: LC-MS/MS (80349): 11-Hydroxy Delta-9 THC, Delta-9 Carboxy THC, Delta-9 THC

0960B Cannabinoids Panel, Blood

Summary of Changes: Specimen Requirements were changed.
Specimen Requirements (Specimen Container) were changed.
Stability was changed.
Scope of Analysis was changed.
Order of Reporting was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80349)]

Specimen Requirements: 1 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Gray top tube (Sodium Fluoride / Potassium Oxalate)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Test Changes

Stability:
- Room Temperature: 30 day(s)
- Refrigerated: 30 day(s)
- Frozen (-20 °C): 30 day(s)

Scope of Analysis: LC-MS/MS (80349): 11-Hydroxy Delta-9 THC, Delta-9 Carboxy THC, Delta-9 THC

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>11-Hydroxy Delta-9 THC</td>
<td>ng/mL</td>
<td>11-Hydroxy Delta-9 THC is an active intermediate metabolite of tetrahydrocannabinol (THC) the active component of marijuana. Usual peak levels: Less than 10% of THC levels after smoking.</td>
</tr>
<tr>
<td>Delta-9 THC</td>
<td>ng/mL</td>
<td>THC concentrations in blood are usually about one-half of serum/plasma concentrations. Usual peak levels in serum for 1.75% or 3.55% THC marijuana cigarettes: 50 - 270 ng/mL at 6 to 9 minutes after beginning smoking, decreasing to less than 5 ng/mL by 2 hrs.</td>
</tr>
</tbody>
</table>

0960FL Cannabinoids Panel, Fluid

Summary of Changes:
- Specimen Requirements were changed.
- Scope of Analysis was changed.
- Order of Reporting was changed.
- Methods/CPT Codes were changed [LC-MS/MS (80349)]

Specimen Requirements:
- 1 mL Fluid
- Refrigerated
- Plastic container (preservative-free)
- Not Required
- None
- None
- LC-MS/MS (80349): 11-Hydroxy Delta-9 THC, Delta-9 Carboxy THC, Delta-9 THC

0960SP Cannabinoids Panel, Serum/Plasma

Summary of Changes:
- Specimen Requirements were changed.
- Scope of Analysis was changed.
- Order of Reporting was changed.
- Reference Comment was changed.
- Methods/CPT Codes were changed [LC-MS/MS (80349)]
Test Changes

Specimen Requirements: 1 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Serum: Collect sample in Red top tube
Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria: Polymer gel separation tube (SST or PST).
Scope of Analysis: LC-MS/MS (80349): 11-Hydroxy Delta-9 THC, Delta-9 Carboxy THC, Delta-9 THC

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>11-Hydroxy Delta-9 THC</td>
<td>ng/mL</td>
<td>11-Hydroxy Delta-9 THC is an active intermediate metabolite of tetrahydrocannabinol (THC) the active component of marijuana. Usual peak levels: Less than 10% of THC levels after smoking.</td>
</tr>
<tr>
<td>Delta-9 THC</td>
<td>ng/mL</td>
<td>Usual peak levels in serum for 1.75% or 3.55% THC marijuana cigarettes: 50 - 270 ng/mL at 6 to 9 minutes after beginning smoking, decreasing to less than 5 ng/mL by 2 hrs.</td>
</tr>
</tbody>
</table>

0960TI  Cannabinoids Panel, Tissue

Summary of Changes: Test Name was changed.
Scope of Analysis was changed.
Order of Reporting was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80349)]

Scope of Analysis: Method (CPT Code) LC-MS/MS (80349): 11-Hydroxy Delta-9 THC, Delta-9 Carboxy THC, Delta-9 THC

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>11-Hydroxy Delta-9 THC</td>
<td>ng/g</td>
<td>[Reference comment removed]</td>
</tr>
<tr>
<td>Delta-9 THC</td>
<td>ng/g</td>
<td>No reference data available.</td>
</tr>
</tbody>
</table>

8892OF  Delta-9 THC (Qualitative), Oral Fluid (Saliva)

Summary of Changes: Stability was changed.
Methods/CPT Codes were changed [LC-MS/MS (80349)]

Stability: Room Temperature: Undetermined
Refrigerated: 28 day(s)
Frozen (-20 °C): Undetermined
Test Changes

Scope of Analysis: LC-MS/MS (80349): Delta-9 THC
Method (CPT Code)

5850OF Delta-9 THC Confirmation (Qualitative), Oral Fluid (Saliva) (Forensic)

Summary of Changes: Specimen Requirements were changed.
Stability was changed.
Methods/CPT Codes were changed [LC-MS/MS (80349)]

Specimen Requirements: 1 mL Oral Fluid (Saliva)
Transport Temperature: Refrigerated
Specimen Container: Oral Fluid collection device
Light Protection: Not Required
Special Handling: Immunalysis QuantisalTM collection device is preferred. Other collection devices are acceptable; however they may affect the reporting limit of the assay. Pour-off containers from non-Immunalysis QuantisalTM collection devices are acceptable. Samples are stable up to 3 days at room temperature and should be refrigerated thereafter. DO NOT FREEZE the OraSure Intercept® or Immunalysis QuantisalTM collection devices.
Rejection Criteria: None
Stability: Room Temperature: Undetermined
Refrigerated: 28 day(s)
Frozen (-20 °C): Undetermined
Scope of Analysis: LC-MS/MS (80349): Delta-9 THC
Method (CPT Code)

1826SP Dronabinol, Serum/Plasma

Summary of Changes: Specimen Requirements were changed.
Stability was changed.
Scope of Analysis was changed.
Order of Reporting was changed.
Methods/CPT Codes were changed [LC-MS/MS (80349)]

Specimen Requirements: 1 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Serum: Collect sample in Red top tube
Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria: Polymer gel separation tube (SST or PST).
Stability: Room Temperature: 14 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)
Test Changes

Scope of Analysis: LC-MS/MS (80349): 11-Hydroxy Delta-9 THC, Delta-9 Carboxy THC, Delta-9 THC

8897OF Drugs of Abuse (7 Panel) (Qualitative), Oral Fluid (Saliva)

Summary of Changes: Methods/CPT Codes were changed [LC-MS/MS (80349)]

Scope of Analysis: LC-MS/MS (80324, 80346, 80353, 80356, 80358, 80359, 80361, 80362): Amphetamine, Methamphetamine, MDA, MDMA, Diazepam, Nordiazepam, Oxazepam, Temazepam, Chlorzoxazone, Lorazepam, Clonazepam, Alprazolam, Midazolam, Cocaine, Benzoylcegonine, Cocaethylene, Methadone, EDDP, Codeine - Free, Morphine - Free, Hydrocodone - Free, 6-Monoacetylmorphine - Free, Hydromorphone - Free, Oxycodone - Free, Oxymorphone - Free, Dihydrocodeine - Free, Phencyclidine, Dextromethorphan

LC-MS/MS (80349): Delta-9 THC

8888OF ProofPOSITIVE® Drug Impaired Driving/DRE Toxicology Cannabinoids (Qualitative), Oral Fluid (Saliva) (CSA)

Summary of Changes: Methods/CPT Codes were changed [LC-MS/MS (80349)]

Scope of Analysis: LC-MS/MS (80349): Delta-9 THC

4155B Sativex®, Blood

Summary of Changes: Specimen Requirements (Specimen Container) were changed.

Stability was changed.

Scope of Analysis was changed.

Order of Reporting was changed.

Reference Comment was changed.

Methods/CPT Codes were changed [LC-MS/MS (80349)]

Specimen Requirements: 3 mL Blood

Transport Temperature: Refrigerated

Specimen Container: Gray top tube (Sodium Fluoride / Potassium Oxalate), Lavender top tube (EDTA)

Light Protection: Not Required

Special Handling: None

Rejection Criteria: None

Stability: Room Temperature: 30 day(s)

Refrigerated: 30 day(s)

Frozen (-20 °C): 30 day(s)

Scope of Analysis: ELISA (80301): Cannabinoids

Method (CPT Code) LC-MS/MS (80349): 11-Hydroxy Delta-9 THC, Delta-9 Carboxy THC, Cannabidiol, Delta-9 THC
### Test Changes

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>11-Hydroxy Delta-9 THC</td>
<td>ng/mL</td>
<td>Mean peak plasma concentrations of 11-Hydroxy Delta-9 THC at approximately 4 hours following dosing with Sativex® at a low dose (5.4 mg of Delta-9 THC and 5.0 mg of Cannabidiol) were 4.2 +/- 0.7 ng/mL and at a high dose (16 mg of Delta-9 THC and 15 mg of Cannabidiol) were 8.4 +/- 1.2 ng/mL. The ratio of whole blood concentration to plasma concentration is unknown for this analyte.</td>
</tr>
<tr>
<td>Delta-9 Carboxy THC</td>
<td>ng/mL</td>
<td>Mean peak plasma concentrations of Delta-9 Carboxy THC at approximately 5 hours following dosing with Sativex® at a low dose (5.4 mg of Delta-9 THC and 5.0 mg of Cannabidiol) were 110 +/- 31 ng/mL and at a high dose (16 mg of Delta-9 THC and 15 mg of Cannabidiol) were 130 +/- 26 ng/mL. The ratio of whole blood concentration to plasma concentration is unknown for this analyte.</td>
</tr>
<tr>
<td>Cannabidiol</td>
<td>ng/mL</td>
<td>Mean peak plasma concentrations of Cannabidiol at approximately 4 hours following dosing with Sativex® at a low dose (5.4 mg of Delta-9 THC and 5.0 mg of Cannabidiol) were 1.6 +/- 0.4 ng/mL and at a high dose (16 mg of Delta-9 THC and 15 mg of Cannabidiol) were 6.7 +/- 2.0 ng/mL. The ratio of whole blood concentration to plasma concentration is unknown for this analyte. Note: marijuana and Sativex® both contain Delta-9 THC and Cannabidiol; therefore, this test may not be able to differentiate between the two.</td>
</tr>
<tr>
<td>Delta-9 THC</td>
<td>ng/mL</td>
<td>Mean peak plasma concentrations of Delta-9 THC at approximately 3 hours following dosing with Sativex® at a low dose (5.4 mg of Delta-9 THC and 5.0 mg of Cannabidiol) were 5.1 +/- 1.0 ng/mL and at a high dose (16 mg of Delta-9 THC and 15 mg of Cannabidiol) were 15 +/- 3.4 ng/mL. The ratio of whole blood concentration to plasma concentration for Delta-9 THC is approximately 0.50 to 0.60.</td>
</tr>
</tbody>
</table>
Test Changes

Summary of Changes:
- Stability was changed.
- Scope of Analysis was changed.
- Order of Reporting was changed.
- Reference Comment was changed.
- Methods/CPT Codes were changed [LC-MS/MS (80349)]

| Stability: | Room Temperature: 14 day(s) |
| Scope of Analysis: | Refrigerated: 30 day(s) |
| | Frozen (-20 °C): 30 day(s) |
| Method (CPT Code) | ELISA (80301): Cannabinoids |
| | LC-MS/MS (80349): 11-Hydroxy Delta-9 THC, Delta-9 Carboxy THC, Cannabidiol, Delta-9 THC |

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>11-Hydroxy Delta-9 THC</td>
<td>ng/mL</td>
<td>Mean peak plasma concentrations of 11-Hydroxy Delta-9 THC at approximately 4 hours following dosing with Sativex® at a low dose (5.4 mg of Delta-9 THC and 5.0 mg of Cannabidiol) were 4.2 +/- 0.7 ng/mL and at a high dose (16 mg of Delta-9 THC and 15 mg of Cannabidiol) were 8.4 +/- 1.2 ng/mL.</td>
</tr>
<tr>
<td>Delta-9 Carboxy THC</td>
<td>ng/mL</td>
<td>Mean peak plasma concentrations of Delta-9 Carboxy THC at approximately 5 hours following dosing with Sativex® at a low dose (5.4 mg of Delta-9 THC and 5.0 mg of Cannabidiol) were 110 +/- 31 ng/mL and at a high dose (16 mg of Delta-9 THC and 15 mg of Cannabidiol) were 130 +/- 26 ng/mL.</td>
</tr>
<tr>
<td>Cannabidiol</td>
<td>ng/mL</td>
<td>Mean peak plasma concentrations of Cannabidiol at approximately 4 hours following dosing with Sativex® at a low dose (5.4 mg of Delta-9 THC and 5.0 mg of Cannabidiol) were 1.6 +/- 0.4 ng/mL and at a high dose (16 mg of Delta-9 THC and 15 mg of Cannabidiol) were 6.7 +/- 2.0 ng/mL. Note: marijuana and Sativex® both contain Delta-9 THC and Cannabidiol; therefore, this test may not be able to differentiate between the two.</td>
</tr>
<tr>
<td>Delta-9 THC</td>
<td>ng/mL</td>
<td>Mean peak plasma concentrations of Delta-9 THC at approximately 3 hours following dosing with Sativex® at a low dose (5.4 mg of Delta-9 THC and 5.0 mg of Cannabidiol) were 5.1 +/- 1.0 ng/mL and at a high dose (16 mg of Delta-9 THC and 15 mg of Cannabidiol) were 15 +/- 3.4 ng/mL.</td>
</tr>
</tbody>
</table>